Can a sharp beam of radiation tame spreading thyroid cancer?
NCT ID NCT07755423
First seen Aug 10, 2026 · Last updated Aug 11, 2026 · Updated 1 time
Summary
This trial is testing whether a precise, high-dose form of radiation called stereotactic body radiotherapy (SBRT) can control distant metastases in people with stage IV thyroid cancer. The study enrolls patients with up to five metastatic lesions who have already tried systemic therapy. The goal is to see if SBRT can stop the cancer from growing, potentially offering a new treatment option for this advanced stage.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Stereotactic body radiotherapy (SBRT), a precise high-dose radiation technique
- What this could lead to
- If successful, this could offer a new way to control metastatic thyroid cancer, potentially delaying disease progression and improving quality of life for patients who have exhausted systemic options.
- What could go wrong
- This is a small phase II study, so results may not be definitive. SBRT can cause side effects like fatigue or damage to nearby organs, and not all patients may benefit.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 44 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Apr 2026
- Expected to finish
-
Dec 2030
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Distant metastasis of thyroid cancer
- Ages
-
18 to 70 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Participants with primary lesion pathologically confirmed as thyroid cancer, and distant metastatic lesions confirmed either by pathology or by two types of imaging modalities. Based on the investigator's judgment, the participant's distant metastatic lesions are expected to be tolerable to Stereotactic Body Radiotherapy (SBRT). The distant metastases should be oligometastatic (total number of metastatic lesions ≤ 5). 2. Participants who have failed prior systemic therapy. Systemic therapy includes radioactive iodine therapy, immunotherapy, targeted therapy, clinical trial therapy, etc. 3. Age: 18 - 70 years old. 4. KPS ≥ 70. 5. Expected survival period ≥ 3 months. 6. Before treatment, neutrophils ≥ 1.6 × 109/L, hemoglobin ≥ 80g/L, platelets ≥ 80×109/L; creatinine clearance rate ≥ 60 ml/min; non-hepatic metastasis patients (total bilirubin ≤ 1.5 times the upper limit of normal, ALT ≤ 1.5 times the upper limit of normal, AST ≤ 1.5 times the upper limit of normal), hepatic metastasis patients (total bilirubin ≤ 3 times the upper limit of normal, ALT ≤ 3 times the upper limit of normal, AST ≤ 3 times the upper limit of normal, normal coagulation function, Child-Pugh grade A or B, normal liver tissue volume \> 700 mL) 7. Signed informed consent form and willing to complete the study according to the protocol. Exclusion Criteria: 1. Patients who achieved complete remission after comprehensive treatment. 2. Pathologically confirmed as a second primary tumor. 3. Received radiotherapy to the corresponding area and the radiotherapy site overlapped with this one. 4. Uncontrollable malignant pleural or peritoneal effusion. 5. Severe internal medical complications and contraindications to radiotherapy. 6. Pregnant women of childbearing age with positive pregnancy test or lactating women. 7. Active mental disorders or other psychological disorders that affected the patient's signing of informed consent and understanding ability. 8. Uncontrollable infections or active infections, such as immunodeficiency or AIDS patients.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Thyroid cancer stage IV are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
The full official record for this study. This one lists no contact details, but it is the first place any would appear.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Fudan University Shanghai Cancer Center
Shanghai, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.